DE60138033D1 - Medikament auf der basis von ein antihyperglykämikum enthaltenden mikrokapseln mit gesteuerter freisetzung - Google Patents

Medikament auf der basis von ein antihyperglykämikum enthaltenden mikrokapseln mit gesteuerter freisetzung

Info

Publication number
DE60138033D1
DE60138033D1 DE60138033T DE60138033T DE60138033D1 DE 60138033 D1 DE60138033 D1 DE 60138033D1 DE 60138033 T DE60138033 T DE 60138033T DE 60138033 T DE60138033 T DE 60138033T DE 60138033 D1 DE60138033 D1 DE 60138033D1
Authority
DE
Germany
Prior art keywords
hyperglycaemic
medicine
microcapsules
metformin
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138033T
Other languages
English (en)
Inventor
Catherine Castan
Remi Meyrueix
Gerard Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Technologies SA
Original Assignee
Flamel Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Technologies SA filed Critical Flamel Technologies SA
Application granted granted Critical
Publication of DE60138033D1 publication Critical patent/DE60138033D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60138033T 2000-11-17 2001-11-19 Medikament auf der basis von ein antihyperglykämikum enthaltenden mikrokapseln mit gesteuerter freisetzung Expired - Lifetime DE60138033D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0014876A FR2816840B1 (fr) 2000-11-17 2000-11-17 Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
PCT/FR2001/003625 WO2002039984A2 (fr) 2000-11-17 2001-11-19 Medicament a base de microcapsules d'anti-hyperglycemiant a liberation prolongee

Publications (1)

Publication Number Publication Date
DE60138033D1 true DE60138033D1 (de) 2009-04-30

Family

ID=8856604

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138033T Expired - Lifetime DE60138033D1 (de) 2000-11-17 2001-11-19 Medikament auf der basis von ein antihyperglykämikum enthaltenden mikrokapseln mit gesteuerter freisetzung

Country Status (13)

Country Link
US (1) US8197850B2 (de)
EP (1) EP1333816B1 (de)
JP (1) JP2004513913A (de)
CN (2) CN1853617A (de)
AT (1) ATE425745T1 (de)
AU (1) AU2002220796A1 (de)
BR (1) BR0115958A (de)
CA (1) CA2428782C (de)
DE (1) DE60138033D1 (de)
ES (1) ES2324205T3 (de)
FR (1) FR2816840B1 (de)
PT (1) PT1333816E (de)
WO (1) WO2002039984A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
FR2825023B1 (fr) 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
FR2843881B1 (fr) * 2002-09-02 2006-06-02 Flamel Tech Sa Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
AU2003246791A1 (en) 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
EP1545472B1 (de) * 2002-09-28 2010-12-08 McNeil-PPC, Inc. Darreichungsformen zur verzögerten freisetzung mit zwei kernen und einer öffnung
EP1510208A1 (de) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
CA2558259A1 (en) * 2004-03-02 2005-09-15 Poly Coat Pty Ltd Paintable primer system
EP1591114A1 (de) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Verwendung von Metformin und Orlistat zur Behandlung oder Vorbeugung von Obesität
CN101602865B (zh) * 2009-03-13 2011-08-31 王懋 一种乙基纤维素混悬液及其制备方法与应用
CN102869349A (zh) * 2010-03-09 2013-01-09 阿尔科米斯制药爱尔兰有限公司 耐酒精的肠溶药物组合物
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
WO2013077821A1 (en) * 2011-11-23 2013-05-30 Mahmut Bilgic Homogeneous biguanide composition
CN103637999B (zh) * 2013-12-12 2014-12-03 南通联亚药业有限公司 一种多层固体药物剂型
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
MX2016014320A (es) 2014-05-01 2017-05-23 Sun Pharmaceutical Ind Ltd Composiciones de suspension de liberacion prolongada.
MX2017001332A (es) 2014-07-30 2017-08-02 Sun Pharmaceutical Ind Ltd Envase con camara.doble.
EP3288539A4 (de) * 2015-05-01 2019-07-10 Sun Pharmaceutical Industries Ltd Flüssige retard-zusammensetzungen von metformin
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
FR3055800B1 (fr) * 2016-09-15 2020-06-26 Unither Pharmaceuticals Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules
WO2019170840A1 (en) * 2018-03-07 2019-09-12 Anabio Technologies Ltd. A composition for type ii diabetics and for use in providing sustained energy release over time

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
GB9104854D0 (en) * 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
DE69220317T2 (de) * 1991-10-01 1997-10-16 Takeda Chemical Industries Ltd Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JPH08151322A (ja) * 1994-09-30 1996-06-11 Takeda Chem Ind Ltd 経口徐放剤
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
ATE250418T1 (de) 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
JP2000085159A (ja) 1998-09-14 2000-03-28 Ricoh Co Ltd 画像処理方法
DE69939485D1 (de) * 1998-11-12 2008-10-16 Smithkline Beecham Plc Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin
DE19860698A1 (de) 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
ATE390140T1 (de) 1999-11-03 2008-04-15 Bristol Myers Squibb Co Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
ATE399000T1 (de) * 1999-12-28 2008-07-15 Ajinomoto Kk Antidiabetes-zubereitung zur oralen verabreichung
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif

Also Published As

Publication number Publication date
JP2004513913A (ja) 2004-05-13
WO2002039984A3 (fr) 2002-07-11
BR0115958A (pt) 2004-01-06
EP1333816A2 (de) 2003-08-13
FR2816840B1 (fr) 2004-04-09
EP1333816B1 (de) 2009-03-18
CN1474687A (zh) 2004-02-11
CA2428782C (fr) 2013-01-08
CA2428782A1 (fr) 2002-05-23
PT1333816E (pt) 2009-06-23
CN1853617A (zh) 2006-11-01
FR2816840A1 (fr) 2002-05-24
WO2002039984A2 (fr) 2002-05-23
US8197850B2 (en) 2012-06-12
US20040175424A1 (en) 2004-09-09
ES2324205T3 (es) 2009-08-03
AU2002220796A1 (en) 2002-05-27
ATE425745T1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
DE60138033D1 (de) Medikament auf der basis von ein antihyperglykämikum enthaltenden mikrokapseln mit gesteuerter freisetzung
Serrano et al. Riehl's melanosis: pigmented contact dermatitis caused by fragrances
HUP0300642A2 (hu) Antidiabetikus készítmény és alkalmazása
NO875194D0 (no) Baerere, deres fremstilling og anvendelse.
AU740375B2 (en) Use of gastrointestinal lipase inhibitors
Roysarkar et al. Effect of insulin therapy on progression of retinopathy in noninsulin-dependent diabetes mellitus
ATE109979T1 (de) Verwendung von guanidinderivaten zur herstellung eines arzneimittels mit npy-antagonistischer wirkung.
Jackson et al. Another abusable amphetamine
DE59206924D1 (de) Ein flurbiprofen enthaltendes akutarzneimittel und seine verwendung
Warwick et al. Drug points: Serious interaction between warfarin and oral terbinafine
Duhault et al. The pharmacology of S 1702, a new highly effective oral antidiabetic drug with unusual properties. 2. Protective activity of S 1702 on the microvascular system in normal and diabetic rats
O'Malley et al. Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension
ES2108642B1 (es) Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
Channa et al. Hypolgcaemic encephalopathy following surgery on phaeochromocytoma
Remskar et al. Profound circulatory shock following heroin overdose
De Haen The drug lag—Does it exist in Europe?
Torrens et al. Parotid swelling and terbinafine.
JPH0327313A (ja) 生理的用量のビタミンａと治療活性のある各種有効成分とを有する組成物
Floyd Jr et al. Feasibility of adjustment of insulin dose by insulin-requiring type II diabetic patients
Velamoor NMS complicated by diazepam
Townsend et al. Continuing rise in emergency admissions. Visiting elderly patients at home immediately after discharge reduces emergency readmissions.
Beddow et al. Non-insulin dependent diabetes mellitus: an epidemic among Hawaiians.
Alván et al. The validity of the sigmoid Emax model and efficiency concept in diuretic studies.
Parodi et al. Long-term treatment of diabetes with glipizide
KLINE DEXEDRINE

Legal Events

Date Code Title Description
8364 No opposition during term of opposition